科源制药
(301281)
| 流通市值：33.74亿 | | | 总市值：51.50亿 |
| 流通股本：7095.20万 | | | 总股本：1.08亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 331,466,454.4 | 161,302,912.39 | 398,227,849.61 | 302,688,076.14 |
| 营业总成本 | 262,042,515.83 | 128,319,432.51 | 363,809,681.93 | 278,777,760.56 |
| 其他经营收益 | | | | |
| 营业利润 | 65,599,766.05 | 33,400,847.53 | 32,386,693.05 | 28,023,489.32 |
| 利润总额 | 72,655,499.87 | 32,692,682.76 | 16,778,197.93 | 31,944,668.7 |
| 净利润 | 64,470,616.69 | 30,536,072 | 16,376,551.12 | 31,261,045.17 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | 64,470,616.69 | 30,536,072 | 16,376,551.12 | 31,261,045.17 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 764,301,169.64 | 731,572,504.49 | 652,390,779.87 | 633,272,572.62 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,146,716,103.01 | 1,059,223,481.7 | 1,035,274,249.91 | 972,573,730.58 |
| 资产总计 | 1,911,017,272.65 | 1,790,795,986.19 | 1,687,665,029.78 | 1,605,846,303.2 |
| 流动负债: | | | | |
| 流动负债合计 | 331,994,607.54 | 239,674,612.81 | 175,987,292.04 | 112,547,307.04 |
| 非流动负债: | | | | |
| 非流动负债合计 | 149,082,637.23 | 157,726,516.08 | 155,495,990.92 | 121,851,690.85 |
| 负债合计 | 481,077,244.77 | 397,401,128.89 | 331,483,282.96 | 234,398,997.89 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 1,429,530,011.23 | 1,392,300,744.31 | 1,355,550,280.6 | 1,370,849,035.03 |
| 股东权益合计 | 1,429,940,027.88 | 1,393,394,857.3 | 1,356,181,746.82 | 1,371,447,305.31 |
| 负债和股东权益合计 | 1,911,017,272.65 | 1,790,795,986.19 | 1,687,665,029.78 | 1,605,846,303.2 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 185,213,017.08 | 118,535,673.67 | 339,582,259.15 | 218,869,644.87 |
| 经营活动现金流出小计 | 142,955,845.01 | 87,413,694.51 | 296,113,181.46 | 191,629,723.54 |
| 经营活动产生的现金流量净额 | 42,257,172.07 | 31,121,979.16 | 43,469,077.69 | 27,239,921.33 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 271,434,944.43 | 8,300,183.93 | 601,827,035.78 | 513,337,958.8 |
| 投资活动现金流出小计 | 513,762,392.37 | 36,630,358.68 | 480,411,328.23 | 642,972,436.59 |
| 投资活动产生的现金流量净额 | -242,327,447.94 | -28,330,174.75 | 121,415,707.55 | -129,634,477.79 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 93,879,517.66 | 44,398,432.45 | 70,161,627.89 | 55,395,301.38 |
| 筹资活动现金流出小计 | 20,267,951.49 | 1,198,514.62 | 28,378,682.36 | 27,426,656.35 |
| 筹资活动产生的现金流量净额 | 73,611,566.17 | 43,199,917.83 | 41,782,945.53 | 27,968,645.03 |
| 汇率变动对现金及现金等价物的影响 | -748,311.04 | -204,929.59 | 453,917.96 | 488,714.31 |
| 现金及现金等价物净增加额 | -127,207,020.74 | 45,786,792.65 | 207,121,648.73 | -73,937,197.12 |
| 期末现金及现金等价物余额 | 171,684,396.2 | 344,678,209.59 | 298,891,416.94 | 17,832,571.09 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -127,207,020.74 | - | 207,121,648.73 | - |